QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
QQQ   272.48 (+1.86%)
AAPL   111.81 (+1.57%)
MSFT   207.42 (+2.41%)
FB   254.75 (+2.66%)
GOOGL   1,459.82 (+2.08%)
AMZN   3,128.99 (+5.69%)
NVDA   505.51 (+0.96%)
TSLA   424.23 (-5.60%)
BABA   275.29 (+0.54%)
CGC   16.04 (+1.91%)
GE   6.25 (-1.57%)
MU   49.70 (+1.12%)
AMD   77.70 (-0.31%)
T   28.51 (-0.42%)
F   6.78 (-1.31%)
ACB   7.32 (+15.82%)
GILD   63.40 (-1.26%)
NFLX   491.17 (+0.78%)
DIS   127.21 (+1.44%)
BAC   23.94 (-2.17%)
BA   156.80 (+0.29%)
Log in
NASDAQ:CRVS

Corvus Pharmaceuticals Stock Forecast, Price & News

$4.13
-0.17 (-3.95 %)
(As of 09/22/2020 12:00 AM ET)
Add
Compare
Today's Range
$4.01
Now: $4.13
$4.37
50-Day Range
$3.11
MA: $3.89
$4.50
52-Week Range
$1.01
Now: $4.13
$6.88
Volume211,274 shs
Average Volume846,729 shs
Market Capitalization$115.79 million
P/E RatioN/A
Dividend YieldN/A
Beta2.13
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing CPI-006, an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and CPI-818, a small molecule covalent inhibitor of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Read More
Corvus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.42 per share

Profitability

Net Income$-46,670,000.00

Miscellaneous

Employees49
Market Cap$115.79 million
Next Earnings Date11/3/2020 (Estimated)
OptionableNot Optionable
$4.13
-0.17 (-3.95 %)
(As of 09/22/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions

How has Corvus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Corvus Pharmaceuticals' stock was trading at $2.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRVS shares have increased by 52.4% and is now trading at $4.13.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Corvus Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Corvus Pharmaceuticals
.

When is Corvus Pharmaceuticals' next earnings date?

Corvus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Corvus Pharmaceuticals
.

How were Corvus Pharmaceuticals' earnings last quarter?

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) issued its quarterly earnings data on Thursday, July, 30th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.08.
View Corvus Pharmaceuticals' earnings history
.

What price target have analysts set for CRVS?

3 Wall Street analysts have issued 1 year price targets for Corvus Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate Corvus Pharmaceuticals' stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 101.8% from the stock's current price.
View analysts' price targets for Corvus Pharmaceuticals
.

Who are some of Corvus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corvus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Vaxart (VXRT), Miragen Therapeutics (MGEN), OrganiGram (OGI) and Aldeyra Therapeutics (aldx).

Who are Corvus Pharmaceuticals' key executives?

Corvus Pharmaceuticals' management team includes the following people:
  • Dr. Richard A. Miller, Co-Founder, Pres, CEO & Chairman (Age 68)
  • Mr. Leiv Lea, Chief Financial Officer (Age 65)
  • Mr. Daniel W. Hunt J.D., Sr. VP & Chief Bus. Officer (Age 57)
  • Dr. Joseph J. Buggy, Co-Founder & Exec. VP of Discovery Research (Age 52)
  • Dr. William Benton Jones, Sr. VP of Pharmaceutical Devel. (Age 53)

When did Corvus Pharmaceuticals IPO?

(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

What is Corvus Pharmaceuticals' stock symbol?

Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."

Who are Corvus Pharmaceuticals' major shareholders?

Corvus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (6.21%), Russell Investments Group Ltd. (0.14%) and Two Sigma Advisers LP (0.13%). Company insiders that own Corvus Pharmaceuticals stock include Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Peter A Thompson and Richard A Md Miller.
View institutional ownership trends for Corvus Pharmaceuticals
.

Which major investors are selling Corvus Pharmaceuticals stock?

CRVS stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL.
View insider buying and selling activity for Corvus Pharmaceuticals
.

Which major investors are buying Corvus Pharmaceuticals stock?

CRVS stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and Two Sigma Advisers LP. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Leiv Lea, Orbimed Advisors Llc, Peter A Thompson, and Richard A Md Miller.
View insider buying and selling activity for Corvus Pharmaceuticals
.

How do I buy shares of Corvus Pharmaceuticals?

Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Corvus Pharmaceuticals' stock price today?

One share of CRVS stock can currently be purchased for approximately $4.13.

How big of a company is Corvus Pharmaceuticals?

Corvus Pharmaceuticals has a market capitalization of $115.79 million. The company earns $-46,670,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Corvus Pharmaceuticals employs 49 workers across the globe.

What is Corvus Pharmaceuticals' official website?

The official website for Corvus Pharmaceuticals is www.corvuspharma.com.

How can I contact Corvus Pharmaceuticals?

Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]

This page was last updated on 9/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.